CM-Clinical Modeling is Axiogenesis’ screening platform concept currently under development to support drug discovery. Stem cell-derived tissues (heart, liver, neuron etc.) model specific pathological scenarios highly relevant for the identification and stratification of new active pharmaceutical ingredients (APIs).
Based on Cor.At® murine and Cor.4U® human stem cell-derived tissue, we currently focus on the generation of a robust induced cardiac hypertrophy model and a unique screening platform for drug discovery. This profiling platform integrates the discovery of new APIs for cardiac hypertrophy therapy and the existing internal portfolio of safety pharmacology and cardiac toxicology testing, and is used for internal drug discovery efforts as well as a drug discovery service for the pharmaceutical industry.
Axiogenesis’ proprietary hypertrophy platform will fuel pharma pipelines for future cardiomyopathy therapy.